arrow
I

Ingrid Garajová

university hospital of parma
H指数:24
被引数:1,846

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

From trial efficacy to real-world effectiveness: evaluating the generalizability of cisplatin–gemcitabine–durvalumab in advanced biliary tract cancers

从临床试验疗效到真实世界有效性:评估顺铂-吉西他滨-度伐利尤单抗在晚期胆道癌中的普适性

2026-11-040
PRE
Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study

胆道癌患者接受化疗免疫疗法后的预后分层:一项回顾性多中心真实世界研究

Cancer
IF5.1
2026-09-160
PRE
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting

根据TOPAZ-1研究入组标准评估顺铂、吉西他滨和度伐利尤单抗的疗效:一项真实世界环境下的全球性大规模分析

2026-08-160
PRE
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experience

关于免疫治疗时代接受多模式治疗的晚期胆道癌患者的初步报告:一项真实世界多中心经验

2026-03-190
OA
The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer

OligoPanc项目:一项关于寡转移性胰腺癌的跨学科专家共识声明

2026-03-020
PRE
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab

接受顺铂、吉西他滨和度鲁特韦治疗的胆道癌患者中,转移部位对预后的影响

2026-02-270
PRE
The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Carcinoma and Diabetes

二甲双胍对接受阿替利珠单抗/贝伐珠单抗治疗的癌病患者的影响

2026-01-010
PRE
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
Long-term recurrence of PDAC after resection for IPMN: A narrative review of the literature on clinical and biologic predictors

IPMN切除术后PDAC的长期复发: 关于临床和生物学预测因素的文献综述

2025-06-020
PRE
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma

索拉非尼作为阿特珠单抗-贝伐单抗治疗不可切除肝细胞癌的二线治疗的次优结果

2024-12-012
OAAI
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
2024-10-011
OAAI
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Durvalumab联合吉西他滨和顺铂治疗晚期胆道癌: 大量现实世界人口

2024-09-013
PRE
Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LUMACA study

孤立性肺转移瘤在胰腺腺癌患者中的多中心意大利队列研究:LUMACA研究

2024-09-010
PRE